European Scientific foundation for Laboratory Hemato Oncology (ESLHO)

Overview  

ESHLO is an independent body that engages with EHA as an SWG to avoid overlapping activities. 

ESLHO’s objectives are to: 

  • Promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies 
  • Facilitate quality control and education in this field 

We’ll achieve our objectives by:  

  • Supporting the organization of scientific meetings for the innovation/research, standardization, and clinical validation of new tools, technologies and strategies for diagnosis of hematological malignancies and immune monitoring 
  • Organizing educational sessions and symposia, and developing educational materials 
  • Developing and promoting the use of standardized protocols 
  • Organizing (external) quality assessment rounds for which a certificate of participation and performance is provided 

Collaborations with consortia 

ESLHO SWG works with and supports three scientific consortia that implement these activities. 

Euroflow 

The EuroFlow [insert link to www.euroflow.org] consortium aims to develop and standardize fast, accurate, and highly sensitive flow cytometric tests. These can be used for the: 

  • Diagnosis, classification and monitoring of hematological malignancies and primary immunodeficiencies 
  • Evaluation of treatment effectiveness via immune monitoring 

EuroMed 

The EuroMRD [insert link to www.euromrd.org] consortium has developed guidelines for the interpretation of RQ-PCR MRD and NGS-MRD data. These guidelines ensure identical interpretation of MRD data between different laboratories that use the same MRD-based clinical protocol. Furthermore, the EuroMRD guidelines facilitate the comparison of MRD data obtained with different treatment protocols, including those that evaluate new drugs, where MRD might be used as primary endpoint.  

EuroClonality 

The EuroClonality [insert link to www.euroclonality.org] consortium develops novel PCR-based methods that allow detection of gene rearrangements to be used for discrimination between normal and abnormal/malignant lymphoproliferations.  

The EuroClonality-NGS Working Group is part of the EuroClonality Consortium. Its purpose is to research and set standards in IG/TR NGS methodology and its applications in hemato-oncology, hematology, and immunology.  

If you have any questions about ESLHO, please email our SWGs team.  

Share